- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00741715
Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia
15. april 2016 opdateret af: Sanofi
A Multicenter, Randomized, Placebo-controlled, "Factorial" Design, 12-month Study to Evaluate the Efficacy and Safety of AVE5530 25 mg/Day and 50 mg/Day Co-administered With All Registered Atorvastatin Strengths Ranging From 10 mg to 80 mg in Patients With Primary Hypercholesterolemia
The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg) co-administered with all approved doses of atorvastatin in a double-blind comparison with placebo, AVE5530 alone and atorvastatin alone in the management of patients with primary hypercholesterolemia.
The main objective is to evaluate the effects of the association AVE5530+atorvastatin on LDL-C level reduction after 12 weeks of treatment.
The effects of AVE5530+atorvastatin on other lipid parameters will be assessed as secondary objectives
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The study will include a 2 week pre-randomization placebo lead-in phase.
There will be a 12- week double-blind treatment period for both components AVE5530 and atorvastatin, followed by a 40-week period with maintenance of double-blind design for AVE5530 component and open label for atorvastatin component transitioning at 20 mg for all patients with subsequent titration, if necessary, based on regular LDL-cholesterol monitoring.
The treatment period can be variably extended up to approximately 18 months with double-blind for AVE5530 component and open-label for atorvastatin.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
1736
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
New Jersey
-
Bridgewater, New Jersey, Forenede Stater, 08807
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Puerto Rico, Puerto Rico
- Sanofi-Aventis Administrative Office
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Adults with high cholesterol levels either not receiving or willing and able to discontinue ongoing lipid-lowering therapy
Exclusion Criteria:
- LDL-C levels > 250 mg/dL (6.48 mmol/L)
- Triglycerides levels > 350mg/dL (3.95 mmol/L)
Conditions / situations such as:
- presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels
- Active liver disease
- High estimated risk of Coronary Heart Disease
- Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease
- Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive
- Pregnant or breast-feeding women,
- Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product
- Hypersensitivity to any component of atorvastatin
- Concurrent administration of Cytochrome P450 3A4 inhibitors (e.g. cyclosporine, erythromycin, clarithromycin, and azole antifungals) should be avoided as increasing the risk of myopathy with atorvastatin
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Faktoriel opgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: 1
|
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 2
AVE5530 25mg
|
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 3
AVE5530 50mg
|
oral administration once daily in the evening with dinner
|
|
Aktiv komparator: 4
atorvastatin 10mg
|
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 5
atorvastatin 10mg + AVE5530 25mg
|
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 6
atorvastatin 10mg + AVE5530 50mg
|
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
|
|
Aktiv komparator: 7
atorvastatin 20mg
|
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 8
atorvastatin 20mg + AVE5530 25mg
|
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 9
atorvastatin 20mg + AVE5530 50mg
|
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
|
|
Aktiv komparator: 10
atorvastatin 40mg
|
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 11
atorvastatin 40mg + AVE5530 25mg
|
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 12
atorvastatin 40mg + AVE5530 50mg
|
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
|
|
Aktiv komparator: 13
atorvastatin 80mg
|
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 14
atorvastatin 80mg + AVE5530 25mg
|
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
|
|
Eksperimentel: 15
atorvastatin 80mg + AVE5530 50mg
|
oral administration once daily in the evening with dinner
oral administration once daily in the evening with dinner
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentvis ændring fra baseline i beregnet LDL-C
Tidsramme: I uge 12
|
I uge 12
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentvis ændring fra baseline i beregnet LDL-C
Tidsramme: Ved 6 måneder og 12 måneder
|
Ved 6 måneder og 12 måneder
|
|
Percent change from baseline in total cholesterol, HDL-C, TG, Apo-A1, Apo-B and CRP
Tidsramme: At week 12, 6 months and 12 months
|
At week 12, 6 months and 12 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Davidson Michael, MD, Radiant Research - 515 North State Street Suite 2700 Chicago Illinois (US)
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. august 2008
Primær færdiggørelse (Faktiske)
1. maj 2009
Studieafslutning (Faktiske)
1. juni 2009
Datoer for studieregistrering
Først indsendt
25. august 2008
Først indsendt, der opfyldte QC-kriterier
25. august 2008
Først opslået (Skøn)
26. august 2008
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
16. maj 2016
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
15. april 2016
Sidst verificeret
1. april 2016
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Metaboliske sygdomme
- Lipidmetabolismeforstyrrelser
- Hyperlipidæmi
- Dyslipidæmi
- Hyperkolesterolæmi
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antimetabolitter
- Antikolesteræmiske midler
- Hypolipidæmiske midler
- Lipidregulerende midler
- Hydroxymethylglutaryl-CoA-reduktasehæmmere
- Atorvastatin
Andre undersøgelses-id-numre
- EFC6911
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .